Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success

Corvus (CRVS) stock's soquelitinib shows early promise in PTCL & atopic dermatitis, but a $1.24B valuation may be ahead of ...
Seeking Alpha

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early ...
ascopubs.org

Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous ...
ascopubs.org

Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group

In Asia, PTCL diagnosis and management are hindered by the lack of available domain experts, limitations in infrastructure support and funding, and substantial challenges in accessing novel drugs; ...
Nature

Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas

Peripheral T-cell lymphomas (PTCL) are rare cancers, which stand for about 10% of all non-Hodgkin's lymphomas (NHL) (Harris et al., 1994; The.Non-Hodgkin's.Lymphoma.Classification.Project, 1997). They ...